AstraZeneca, Tricog launch project for early diagnosis of heart attacks
This project addresses the unmet need for early diagnosis and intervention for patients with suspected heart attack by enabling cloud-based artificial intelligence supported interpretation of electrocardiograms, routing patients to the nearest cath Labs or fibrinolysis centres
New AstraZeneca tie-up to explore vaccine tech for cancer, heart disease
An Imperial College London start-up has tied up with British-Swedish biopharmaceutical major AstraZeneca to explore the therapeutic uses of its vaccine technology
AstraZeneca Pharma India gets DCGI nod to import, market Selumetinib
Permission paves the way for launch of 10 and 25 mg capsules in India AstraZeneca Pharma India Ltd - 506820 - Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 From The Drugs Controller General Of India For Selumetinib 10 Mg & 25 Mg Capsule
This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule. Selumetinib 10 mg & 25 mg capsule is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN). The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses.
Covid-19 vaccine: AstraZeneca to develop Imperial's new RNA technology
Under the deal, VaxEquity, a start-up founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met Not many places left for Covid to evade immunity: UK vaccine creator
There aren't many places left for the COVID-19 virus to mutate and evade immunity as it will only get weaker with time, said the creator of the Oxford-AstraZeneca vaccine Vaccine certification for travel must meet minimum criteria', says UK
It follows Covishield, the Serum Institute of India manufactured Oxford/AstraZeneca vaccine, being added as eligible to an expanded UK travel advisory on Wednesday ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window
This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the Shares of the Company shall be closed from today i.e. Thursday, September 16, 2021 and the same shall reopen after 48 hours from the declaration of Unaudited Financial Results of the Company for the quarter ending September 30, 2021. AstraZeneca, EC settle vax-supply row, end litigation
The development in Europe does not involve India's Serum Institute
AstraZeneca's antibody drug prevents Covid-19 in high-risk groups
Results from Astra's study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement Friday